Psychedelic Microdosing - Just a Placebo Effect?

Authors: Balázs Szigeti, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris, David Erritzoe Published: March 2, 2021 What is microdosing? Psychedelic microdosing involves consuming psychedelics such as LSD or psilocybin mushrooms at a microdose, which is typically about 10% of a recreational dose. Microdosing is gaining increasing popularity, with  …

Study Drug Sessions - Insights on psychedelic microdosing

Laura Kaertner – Insights on psychedelic microdosing Laura Kaertner is a research assistant at the Centre of Psychedelic Research at Imperial College London where she researches the effects of psychedelic microdosing. Her primary role is in the organisation and set-up of a large-scale observational microdosing study. Microdosing has gained significant media interest, with media reports  …


2019: A year of expansion in psychedelic research, industry, and deregulation

Authors: Jacob S Aday, Emily K Bloesch, Christopher C Davoli Published: November 25, 2020 Public and scientific interest into psychedelic drugs has grown steadily over much of the last two decades, before an exponential increase in recent years. We contend that 2019, in particular, involved myriad notable changes in the science, industry, and deregulation of  …

Improved colour blindness symptoms associated with recreational psychedelic use

Authors: JEC Anthony, A Winstock, JA Ferris, DJ Nutt Published: November 2, 2020 It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug ingestion, several participants had written to the authors describing how symptoms of their colour blindness had improved. The Global Drugs Survey  …

Launch of the Medical Psychedelics Working Group

On Tuesday July 14th, 2020, Drug Science will launch a new working group of experts, policy makers and scientists. Its primary role is to campaign for the rescheduling of all psychedelic drugs for research and medical purposes. However, current UK regulations have created serious and considerable barriers to legitimate research associated with Schedule 1 regulations.  …

#7 - Ethnopharmacology

Professor David Nutt begins season two of the Drug Science Podcast by taking a deep dive into entheogenic plants with a legend of the psychedelic renaissance – Dennis McKenna. Dennis deliberates on his life’s work, ethnobotany, innovation within psychedelic industry, the therapeutic potential of DMT and the indigenous use of ayahuasca. Dennis McKenna’s research has  …


Law on psychedelic drugs blocks vital medical research

Professor David Nutt’s recent comment in ‘The Times‘ addresses how the ‘Law on psychedelic drugs blocks vital medical research‘. In the 1950s, psychedelics­ — LSD and psilocybin (magic mushrooms) in particular — were seen as the great breakthrough in psychiatry, offering effective treatments for hitherto untreatable disorders. For 15 years, while they were the subject  …